Abstract
Multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 plays a role in the development of Alzheimer’s disease. However, changes in its expression in the brain or cerebrospinal fluid are not fully specific for this type of dementia. Our previous study revealed that complexes of the enzyme and amyloid β in cerebrospinal fluid could serve as a more specific biomarker of Alzheimer’s disease than either the enzyme or amyloid β individually when compared to autoimmune multiple sclerosis. In this study, enzyme-linked immunosorbent assay and the surface plasmon resonance biosensor method were used to analyse cerebrospinal fluid of patients with various neuroinflammatory diseases. Significant differences in the levels of the total enzyme, complexes, amyloid β 1-42 and total τ/phospho-τ were found in Alzheimer’s disease patients while differences in complexes, total amyloid β and amyloid β 1- 42 were observed in patients with neuroinflammatory diseases (except for multiple sclerosis) when compared to nonneuroinflammatory controls. The interactions of the enzyme with amyloid β appeared to depend strongly on neuroinflammation-sensitive amyloid β. Our data demonstrated that oligomerisation/aggregation of intracellular amyloid β peptides was important in Alzheimer’s disease while extracellular amyloid β could play a role in neuroinflammatory diseases. Phospho-τ is currently the best biomarker of Alzheimer’s disease.
Keywords: Amyloid β, mitochondrial enzyme, Alzheimer’s disease, neuroinflammation
Current Alzheimer Research
Title:Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease
Volume: 10 Issue: 2
Author(s): Zdena Kristofikova, Daniela Ripova, Ales Bartos, Marketa Bockova, Katerina Hegnerova, Jan Ricny, Linda Cechova, Monika Vrajova and Jiri Homola
Affiliation:
Keywords: Amyloid β, mitochondrial enzyme, Alzheimer’s disease, neuroinflammation
Abstract: Multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 plays a role in the development of Alzheimer’s disease. However, changes in its expression in the brain or cerebrospinal fluid are not fully specific for this type of dementia. Our previous study revealed that complexes of the enzyme and amyloid β in cerebrospinal fluid could serve as a more specific biomarker of Alzheimer’s disease than either the enzyme or amyloid β individually when compared to autoimmune multiple sclerosis. In this study, enzyme-linked immunosorbent assay and the surface plasmon resonance biosensor method were used to analyse cerebrospinal fluid of patients with various neuroinflammatory diseases. Significant differences in the levels of the total enzyme, complexes, amyloid β 1-42 and total τ/phospho-τ were found in Alzheimer’s disease patients while differences in complexes, total amyloid β and amyloid β 1- 42 were observed in patients with neuroinflammatory diseases (except for multiple sclerosis) when compared to nonneuroinflammatory controls. The interactions of the enzyme with amyloid β appeared to depend strongly on neuroinflammation-sensitive amyloid β. Our data demonstrated that oligomerisation/aggregation of intracellular amyloid β peptides was important in Alzheimer’s disease while extracellular amyloid β could play a role in neuroinflammatory diseases. Phospho-τ is currently the best biomarker of Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Kristofikova Zdena, Ripova Daniela, Bartos Ales, Bockova Marketa, Hegnerova Katerina, Ricny Jan, Cechova Linda, Vrajova Monika and Homola Jiri, Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease, Current Alzheimer Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567205011310020006
DOI https://dx.doi.org/10.2174/1567205011310020006 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research All for Statins and Statins for All; An Update
Current Pharmaceutical Design Is There Any Scientific Basis of Hawan to be Used in the Alzheimer’s Disease Prevention/Cure?
Current Traditional Medicine Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic
CNS & Neurological Disorders - Drug Targets Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease
Current Alzheimer Research Blood-based Amyloid and Tau Biomarker Tests For Alzheimer’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Efficacy of Pentoxifylline in the Management of Microalbuminuria in Patients with Diabetes
Current Diabetes Reviews Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
CNS & Neurological Disorders - Drug Targets Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry Nitric Oxide’s Involvement in the Spectrum of Psychotic Disorders
Current Medicinal Chemistry Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management
CNS & Neurological Disorders - Drug Targets Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research